Results of a Clinical Study of Pevonedistat (Pev),a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)

被引：10
|
作者：
Swords, Ronan T. [1 ]
Coutre, Steven [2 ]
Maris, Michael B. [3 ]
Zeidner, Joshua F. [4 ]
Foran, James M. [5 ]
Cruz, Jose C. [6 ]
Erba, Harry P. [7 ,8 ]
Berdeja, Jesus G. [9 ]
Tam, Wayne [10 ]
Vardhanabhuti, Saran [11 ]
Dobler, Iwona [11 ]
Faessel, Helene M. [12 ]
Dash, Ajeeta B. [13 ]
Sedarati, Farhad [14 ]
Dezube, Bruce J. [14 ]
Savona, Michael R. [15 ,16 ]
机构：
[1] Univ Miami, Sylvester Comprehens Canc Ctr, Hematol Oncol, Miami, FL USA
[2] Stanford Univ, Med, Stanford, CA USA
[3] Colorado Blood Canc Inst, Denver, CO USA
[4] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[5] Mayo Clin, Jacksonville, FL USA
[6] Texas Transplant Inst, Bone Marrow Transplant, San Antonio, TX USA
[7] Univ Alabama Birmingham, Div Hematol, Internal Med, Birmingham, AL USA
[8] Univ Alabama Birmingham, Div Oncol, Internal Med, Birmingham, AL USA
[9] Sarah Cannon Res Inst, Nashville, TN USA
[10] Weill Cornell Med Ctr, Pathol & Lab Med, New York, NY USA
[11] Takeda Pharmaceut Co Ltd, Millennium Pharmaceut Inc, Biostatist, Cambridge, MA USA
[12] Takeda Pharmaceut Co Ltd, Millennium Pharmaceut Inc, Quantitat Clin Pharmacol, Cambridge, MA USA
[13] Takeda Pharmaceut Co Ltd, Millennium Pharmaceut Inc, Translat & Biomarker Res, Cambridge, MA USA
[14] Takeda Pharmaceut Co Ltd, Millennium Pharmaceut Inc, Oncol Clin Res, Cambridge, MA USA
[15] Vanderbilt Univ Sch Med, Internal Med, Nashville, TN USA
[16] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.98.98
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
98
引用
收藏
页数：8
相关论文
共 44 条
  • [21] MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules.
    Kauh, J. S.
    Shapiro, G.
    Cohen, R. B.
    Clark, J. W.
    Harvey, R. D.
    Cleary, J. M.
    Mahalingam, D.
    Kuan, S.
    McDonald, A.
    Berger, A.
    Dezube, B.
    Sarantopoulos, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study
    Swords, Ronan T.
    Erba, Harry P.
    DeAngelo, Daniel J.
    Smith, Peter G.
    Pickard, Michael D.
    Dezube, Bruce J.
    Giles, Francis J.
    Medeiros, Bruno C.
    BLOOD, 2010, 116 (21) : 288 - 288
  • [23] MLN4924, A Novel First in Class Small Molecule Inhibitor of the Nedd8 Activating Enzyme (NAE), Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia.
    Swords, Ronan T.
    Kelly, Kevin R.
    Smith, Peter G.
    Gansey, James J.
    Mahalingam, Devalingam
    Padmanabhan, Swaminathan
    O'Dwyer, Michael C.
    Nawrocki, Steffan T.
    Giles, Francis J.
    Carew, Jennifer S.
    BLOOD, 2009, 114 (22) : 423 - 423
  • [24] OVERALL SURVIVAL (OS) AND CLINICAL OUTCOMES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE (AZA) OR INTENSIVE CHEMOTHERAPY (IC) IN THE AZA-AML-001 STUDY
    Doehner, H.
    Selleslag, D.
    Cavenagh, J.
    Seymour, J. F.
    Minden, M.
    Recher, C.
    Martinelli, G.
    Mayer, J.
    Font Lopez, P.
    Kim, H. -J.
    Chou, W. -C.
    Kew, A.
    Min, Y. H.
    Songer, S.
    Lucy, L. M.
    Beach, C.
    Dombret, H.
    HAEMATOLOGICA, 2015, 100 : 215 - 216
  • [25] OVERALL SURVIVAL (SG) AND CLINICAL RESULTS IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (LMA) TREATED WITH AZACITIDINE (AZA) OR WITH INTENSIVE CHEMOTHERAPY (QI) IN AZA-AML-001
    Font Lopez, P.
    Dombret, H.
    Selleslag, D.
    Songer, S.
    Lucy Lela, M.
    Beach, C. L.
    Doeher, H.
    HAEMATOLOGICA, 2015, 100 : 22 - 23
  • [26] ACTIVITY OF MLN4924, A NOVEL FIRST IN CLASS SMALL MOLECULE INHIBITOR OF THE NEDD8 ACTIVATING ENZYME, IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA
    Swords, T.
    Kelly, K.
    Smith, P.
    Mahalingam, D.
    O'Dwyer, M.
    Nawrocki, S.
    Giles, F.
    Carew, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 305 - 306
  • [27] OVERALL SURVIVAL (OS) AND CLINICAL OUTCOMES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE (AZA) OR LOW-DOSE CYTARABINE (LDAC) IN THE AZA-AML-001 STUDY
    Seymour, J. F.
    Doehner, H.
    Kumar, R.
    Stone, R. M.
    Wierzbowska, A.
    Bernal del Castillo, T.
    Falantes, J.
    Delaunay, J.
    Sabloff, M.
    Voso, M. T.
    Kim, I.
    Ram, R.
    Gau, J. P.
    Songer, S.
    Lucy, L. M.
    Beach, C.
    Dombret, H.
    HAEMATOLOGICA, 2015, 100 : 381 - 381
  • [28] Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL)
    Mueller-Tidow, Carsten
    Tschanter, Petra
    Krug, Utz
    Goellner, Stefanie
    Roellig, Christoph
    Thiede, Christian
    Koschmieder, Anja
    Dugas, Martin
    Gerss, Joachim
    Butterfass-Bahloul, Trude
    Wagner, Ruth
    Krause, Stefan W.
    Kaiser, Ulrich
    Kunzmann, Volker
    Steffen, Bjoern
    Noppeney, Richard
    Herr, Wolfgang
    Baldus, Claudia D.
    Schmitz, Norbert
    Goetze, Katharina
    Reichle, Albrecht
    Kaufmann, Martin
    Neubauer, Andreas
    Schaefer-Eckart, Kerstin
    Haenel, Mathias
    Peceny, Rudolf
    Bea, Haack
    Meredith, Lilly
    Frickhofen, Norbert
    Kiehl, Michael G.
    Giagounidis, Aristoteles A. N.
    Goerner, Martin
    Repp, Roland
    Naumann, Ralph
    Link, Hartmut
    Kiani, Alexander
    Koschmieder, Steffen
    Bruemmendorf, Tim H.
    Serve, Hubert
    Ehninger, Gerhard
    Berdel, Wolfgang E.
    BLOOD, 2014, 124 (21)
  • [29] Phase 3 study of first line pevonedistat (PEV) plus azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML).
    Sekeres, Mikkael A.
    Fram, Robert J.
    Hua, Zhaowei
    Ades, Lionel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics
    Stevens, Brett M.
    Winters, Amanda
    Gutman, Jonathan A.
    Fullerton, Aaron
    Hemenway, Gregory
    Miltgen, Nicholas
    Wei, Qi
    Abbasi, Taher
    Vali, Shireen
    Singh, Neeraj Kumar
    Drusbosky, Leylah M.
    Cogle, Chris R.
    Hammes, Andrew
    Jordan, Craig T.
    Pollyea, Daniel A.
    BLOOD, 2017, 130
12345